Ecolectro | $10,500,000 | (Nov 15, 2024)
Workflow | $3,000,000 | (Nov 15, 2024)
runQL | $1,600,000 | (Nov 15, 2024)
Cullgen Inc.
United States
- San Diego, California
- 09/05/2023
- Unknown
- $40,000,000
Cullgen is a biopharmaceutical company that has developed protein degradation technology that utilizes the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Our technology, which we call uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) has the potential to address a broad range of intracellular disease targets, including those representing the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to as undruggable targets. In addition to using our uSMITE™ platform to build our own pipeline of protein degradation product candidates, we are also developing a portfolio of novel E3 ligands. You can learn more information about Cullgen on our website: www.Cullgen.com
- Industry Biotechnology Research
- Website https://www.cullgen.com/
- LinkedIn https://www.linkedin.com/company/cullgen/
ELICIT PLANT | $48,000,000 | (Nov 15, 2024)
Sunthetics | $4,000,000 | (Nov 15, 2024)
Vaulted Deep | $32,300,000 | (Nov 15, 2024)
Serenity | $5,500,000 | (Nov 15, 2024)
Airbound | $1,700,000 | (Nov 15, 2024)
Influur | $10,000,000 | (Nov 15, 2024)
Naturbeads | $9,890,632 | (Nov 15, 2024)
TestSprite | $1,500,000 | (Nov 15, 2024)
Impilo | $11,500,000 | (Nov 15, 2024)